| Xin Wang,Yingying Xie,Guanjun Jing,Fang Yu,Yinghong Ren. The efficacy and safety of thalidomide for treating metastatic breast cancer: a systematic review. Oncol Transl Med, 2020, 6: 98-102. |
| The efficacy and safety of thalidomide for treating metastatic breast cancer: a systematic review |
| Received:March 14, 2019 Revised:June 02, 2020 |
| View Full Text View/Add Comment Download reader |
| KeyWord:thalidomide; metastatic breast cancer (MBC); vascular endothelial growth factor (VEGF); tumor necrosis factor-α (TNF-α) |
| Author Name | Affiliation | E-mail | | Xin Wang | 1 Department of Oncology, Shangluo Central Hospital | wx780@163.com | | Yingying Xie | 1 Department of Oncology, Shangluo Central Hospital | | | Guanjun Jing | 1 Department of Oncology, Shangluo Central Hospital | | | Fang Yu | 1 Department of Oncology, Shangluo Central Hospital | | | Yinghong Ren | 1 Department of Oncology, Shangluo Central Hospital | 452131257@qq.com |
|
| Hits: 7104 |
| Download times: 7957 |
| Abstract: |
| Objective This systematic review was conducted to investigate the efficacy and safety of thalidomide in
metastatic breast cancer (MBC).
Methods Based on pre-defined inclusion and exclusion criteria, data were independently collected from
different databases by three investigators. Overall, three studies were included.
Results The included studies indicated that no patient achieved a partial or complete response from
different thalidomide dose levels. Thalidomide was well-tolerated at doses of 100 mg, 200 mg, and 400 mg.
In all three studies, common side effects included constipation, somnolence, fatigue, peripheral neuropathy,
and dry mouth. Circulating angiogenic factors were not significantly correlated with disease progression.
Conclusion The available evidence indicates that single-agent thalidomide has little or no activity in
patients with MBC. |
| Close |
|
|
|